Navigation Links
ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2010
Date:4/1/2011

pense for the fourth quarter of 2010 was $14,000 as compared to $13,000 for the fourth quarter of 2009 and consisted of financing costs for our insurance policies and interest costs related to regulatory fees.

For the year ended December 2010, interest expense was $51,000 as compared to $15,000 for the same period of 2009.  The increase of approximately $36,000 is attributable to interest costs related to regulatory fees.

Impairment of Intangible Assets

Yearly, we performed an evaluation of our intangible assets for purposes of determining possible impairment.  In 2010 the fair value of our intangible assets exceeded the recorded remaining book value.  In 2009 we recognized an impairment charge of $717,000 associated with the valuation of the Zindaclin® patent.

Loss on Sale of Intangible Assets

For the year ended December 2010, loss on sale of intangible assets was $858,000 and consisted of the June 2010 divestiture of our Zindaclin® intangible asset.  There was no intangible asset divestiture for the year ended December 2009.

Mr. Gray added, "There were many achievements in 2010 that favorably position the Company for growth in 2011 and beyond including, the granting of the CE Mark, the Distribution Agreement with Novartis, the Altrazeal® Licensing Agreement for China and the significant progress that has been made establishing the base business from which Altrazeal® can favorably compete in the U.S. wound care market. The clinical data that has been developed shows significant pain reduction, the ability to provide a pharmacoeconomic benefit (lower treatment cost and improved clinical outcomes) in the treatment of diabetic foot ulcers, venous leg ulcers and geriatric trauma which are three of the largest segments of the wound care market, and gives us a strong marketing platform. Also, the ability to increase the interval between dressing changes ideally positions Altr
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update
2. ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®s Label Claim
3. ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex
4. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
5. ULURU Inc. to Raise $500,000 in Registered Direct Offering
6. ULURU Inc. Reports Third Quarter 2010 Financial Results
7. ULURU Inc. Provides Altrazeal® Clinical Update
8. ULURU Inc. Announces Conference Call
9. ULURU Inc. Reports Second Quarter 2010 Financial Results
10. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
11. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... , Aug. 20, 2014 Trovagene, Inc. (NASDAQ: ... today that results from two clinical studies will be ... the Company,s urine-based diagnostic test for the detection of ... conference is scheduled to take place in ... 25 th . Additionally, a new U.S. patent was ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
(Date:8/20/2014)... PA (PRWEB) August 20, 2014 A ... products from the blood did not improve survival chances ... analysis led by experts at the University of ... published online today in the journal PLOS One ... standardly used for people with sudden kidney failure, may ...
(Date:8/20/2014)... Steven Reinberg HealthDay Reporter ... disorder that dismantles a baby,s immune system is twice as ... 3 million infants says. This is the first evaluation ... treatable condition known as severe combined immunodeficiency (SCID), or "Bubble ... of this condition by the boy in the bubble, who ...
(Date:8/20/2014)... Caddis Partners LLC, has built one of the most ... in recent years, developing or acquiring 2 million square ... more than $100 million last year alone. , In ... geographic regions and a wider array of product types ... an enhanced brand identity that includes a new logo, ...
(Date:8/20/2014)... 20, 2014 Understanding the impact ... physician stakeholders networks impacting the launch of new ... Canada, and Emerging Markets. , This Flash Report ... on stakeholder management needs for the melanoma market. ... targeted therapy investigational agents that are further improving ...
(Date:8/20/2014)... MI (PRWEB) August 20, 2014 In its ... drug and alcohol treatment program that gets clients off to ... recovery they can believe in, is highlighting an important and ... be heeded by everyone who wants to understand the insidious ... are of the belief that drug abuse targets a certain ...
Breaking Medicine News(10 mins):Health News:Pitt Analysis Questions Use of Acute Hemodialysis Treatment 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 2Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 3Health News:Caddis Rebrands to Emphasize Its Growth, Expanded Capabilities 4Health News:Download HeartBeat Experts White Paper: A Stakeholder Engagement Strategy is Critical for the Evolving Melanoma Treatment Setting 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3
... Systems Operations, Security and, Maintenance ... ARLINGTON, Va., Oct. 16 Vangent, ... and business process outsourcing,solutions, today announced it ... Information and Decision Support (EIDS) Infrastructure,Operations, Security ...
... risk of asthma than their urban counterparts or even ... a University of Alberta study. , Analysis of ... 12 years in the ongoing Canadian National Longitudinal Survey ... in a farming environment had a lower risk of ...
... COLUMBUS, Ga., Oct. 16 Aflac Incorporated,(NYSE: AFL ... financial,results after the market closes on October 23, 2007. ... will,webcast a conference call scheduled for 9:30 a.m. (EDT) ... and CEO Dan,Amos will discuss third quarter results and ...
... STA Travel, the world,s largest student,and youth travel organization, and ... pandemic in Africa. Through the "Good Cents,Initiative", college students across ... to compose a song, direct a video or write an,essay ... where they,will work side by side with Keep A Child ...
... "I would have never,guessed that some of the best ... come from Planned Parenthood, the largest,abortion chain in the ... Days for Life., "People in more than 80 ... about half of the vigils are being conducted outside ...
... is commonly thought that men with low IQs sexually ... deviance, new research has found the men may sexually ... previously taken. , A team of North American ... an intellectual disability and a history of sexual offence ...
Cached Medicine News:Health News:Vangent, Inc. Awarded Contract to Support Military Health System's Executive Information and Decision Support Program 2Health News:Farm kids have lower risk of asthma, study shows 2Health News:Aflac Incorporated to Release Third Quarter Results On October 23, 2007 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 2Health News:STA Travel and Keep a Child Alive Ask College Students to Demonstrate Their 'Good Cents' 3Health News:40 Days for Life Reaches Halfway Point; Planned Parenthood Now in Crisis Mode 2Health News:'Corrective' sex education may make sexual offenders more dangerous 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: